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ABSTRACT
Objective To assess the effectiveness of the pandemic
influenzaA/H1N1vaccineusedin Canadaduringautumn
2009.
Design Test negative incident case-control study based
on sentinel physician surveillance system.
Setting Community based clinics contributing to sentinel
networks in British Columbia, Alberta, Ontario, and
Quebec, Canada.
Participants552patientswhopresentedtoasentinelsite
within seven days of onset of influenza-like illness during
the primary analysis period between 8 November and 5
December 2009; participants were mostly (>80%)
children and adults under 50 years old.
Interventions Monovalent AS03 adjuvanted pandemic
influenza A/H1N1 vaccine as the predominant
formulation (>95%) distributed in Canada.
Main outcome measures Vaccine effectiveness
calculated as 1−(odds ratio for influenza in vaccinated
(received pandemic H1N1 vaccine at least two weeks
before onset of influenza-like illness) versus
unvaccinated participants), with adjustment for age,
comorbidity, province, timeliness of specimen collection,
and week of illness onset. Sensitivity analyses explored
the influence of varying analysis periods between 1
Novemberand31December,receiptoftrivalentseasonal
influenza vaccine, and restriction to participants without
comorbidity.
Results During the primary analysis period, pandemic
H1N1 was detected by reverse transcription polymerase
chain reaction in 209/552 (38%) participants; rates were
highest in children and young adults (40%) and lowest in
people aged 65 or over (9%). Among the 209 cases, 35
(17%) reported comorbidity compared with 80/343
(23%) controls. Two (1%) cases had received pandemic
H1N1 vaccine at least two weeks before the onset of
illness, compared with 58/343 (17%) controls, all single
dose. Adjusted vaccine effectiveness overall was 93%
(95%confidence interval69% to 98%). Highestimatesof
vaccine protection—generally at least 90%—were
maintained across most sensitivity analyses.
Conclusions Although limited by a small number of
vaccine failures, this study suggests that the monovalent
AS03 adjuvanted vaccine used in Canada during autumn
2009 was highly effective in preventing medically
attended, laboratory confirmed pandemic H1N1 illness,
with reference in particular to a single dose in children
and young adults.
INTRODUCTION
In Canada, public health authorities sought to immu-
nise the population against pandemic influenza
A/H1N1 during the autumn of 2009. They selected a
monovalent AS03 adjuvanted product as the primary
formulation for distribution in Canada (about 23 mil-
lion doses; 95%). A second unadjuvanted product
made up most of the remaining vaccine distributed
(about 1.1 million doses; <5%) and was targeted pri-
marily at women in the first half of pregnancy. Both
products were domestically manufactured in Laval,
Quebec,CanadaanddistributedbyGlaxoSmithKline.
Asmallquantityofunadjuvantedvaccinewasalsosup-
plied by CSL Biotherapies from Australia (about
200000 doses; <1%). Canada procured enough pan-
demic vaccine to immunise the entire population free
of charge. Supply was initially limited, however,
requiring sequencing of roll-out of vaccine (web
appendixA).Inparticipatingprovinces,thefirsttarget
groups—typically consisting of very young children,
pregnant women, and people aged over 65 with
comorbidity—began receiving vaccine on 26 October
2009 (week 43). Vaccine was made available to
sequential groups over the ensuing four weeks and
finally to all members of the population starting from
19-25 November 2009 (weeks 46-47). Some people
who did not belong to sequenced groups may have
received vaccine before this date, at the discretion of
immunisation providers.
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Japan, and North America showed that a single dose
of the AS03 adjuvanted vaccine produced in Canada
was highly immunogenic.
1 Fold rises in geometric
mean titres after a single dose were substantially
above thresholds specified by the European Agency
for the Evaluation of Medicinal Products (EMEA) for
approval of seasonal vaccines.
2 Results from these
trials among population groups including children,
youngadults,andadultsagedover60showedseropro-
tection rates exceeding 90%.
134A randomised trial of
children aged 6 months to 12 years (n=937) showed
that AS03 adjuvanted pandemic H1N1 vaccine was
more immunogenic than a non-adjuvanted whole
virus formulation, especially among children under
3 years of age.
5
One the basis of these findings, health authorities
anticipated that a single dose of the AS03 adjuvanted
pandemic H1N1 vaccine administered in Canada
would be highly protective in all age groups. Several
caveats to the interpretation of immunogenicity data
exist, however. Firstly, quantification of immunogeni-
cityistypicallybasedonthehaemagglutinationinhibi-
tion assay, which may not be an accurate measure of
functional antibody response.
6 Secondly, seroprotec-
tive thresholds cited by the EMEA for the approval
of seasonal influenza vaccines have not been specifi-
cally assessed for the novel pandemic virus.
2 Thirdly,
trials of immunogenicity assess antibody response to
the specific reference strain of vaccine selected as that
considered most likely to dominate. The pool of circu-
lating viruses may instead include a mix of variants,
resulting in reduced clinical effectiveness. Although
viruses detected globally through the 2009-10 influ-
enza surveillance period mostly retained a close
match to the pandemicvaccine component,
7 sampling
may not be fully representative of circulating strains.
Finally, the number of participants included in pre-
marketing immunogenicity trials, especially among
children, was small and details of the characteristics
of participants were inadequate to enable broad and
reliable generalisation to the full population
immunised.
134
For the above reasons, approval of pandemic vac-
cine based on pre-marketing immunogenicity results
was accompanied in several countries by the expecta-
tion that the effectiveness of the vaccine would also be
assessed with post-marketing epidemiological meth-
ods. Here, we report estimates of the effectiveness of
the AS03 adjuvanted pandemic H1N1 vaccine most
used in Canada during the autumn of 2009 based on
Canada’s well established sentinel surveillance system
and predicated on a test negative incident case-control
design.
METHODS
Sentinel vaccine effectiveness monitoring system
As previously described, networks of sentinel physi-
cians in British Columbia, Alberta, Quebec, and
Ontario contribute to influenza surveillance and mon-
itoring of vaccine effectiveness annually in Canada.
8-11
Duringthepandemic,andaspartofsurveillanceactiv-
ities,sentinelphysicianswerespecificallyexemptfrom
restrictions on testing that applied to clinicians outside
thenetwork.Sentinelphysiciansareprovidedwithkits
for monitoring vaccineeffectivenessto submitrespira-
toryspecimens(nasalornasopharyngeal)forinfluenza
testing accompanied by epidemiological information
collected from eligible consenting patients. Patients
are eligible if they present to one of more than 500
contributing community based physicians within
seven days of onset of influenza-like illness. Influ-
enza-like illness is defined as the acute onset of fever
and cough and one or more of sore throat, myalgia,
arthralgia,andprostration.Clinicaldiscretionis incor-
porated into the decision to test. All participants gave
informed oral consent to be included in vaccine effec-
tiveness monitoring, and this was documented on the
requisition. Only specimens accompanied by confir-
mation of consent and complete information on the
questionnaire are included in the analysis of vaccine
effectiveness.
Information collected about immunisation status
included the type (adjuvanted or unadjuvanted) and
number of doses of 2009-10 pandemic vaccine
received and whether the last dose was at least two
weeks before the onset of illness. The questionnaire
also captured the presence (yes/no to any) of one or
more of the following high risk chronic conditions
defined by the National Advisory Committee on
Immunization: heart, lung, renal, metabolic, blood,
and immune conditions or conditions that compro-
mise the management of respiratory secretions and
increasetheriskofaspiration.
12Informationonreceipt
of trivalent inactivated influenza vaccine during the
2009-10, 2008-9, or 2007-8 seasons was also collected.
Immunisationregistriesdonot exist inmost provinces
of Canada, so the vaccine status based on patients’
report cannot be further verified.
Vaccines
Arepanrix (GlaxoSmithKline) is a monovalent AS03
adjuvanted and formalin inactivated deoxycholate
split virion product manufactured in Laval, Quebec.
It made up about 95% of the pandemic H1N1 vaccine
distributed in Canada during the autumn 2009 immu-
nisation campaign. A 0.5 mL dose of Arepanrix con-
tained 3.75 µg haemagglutinin derived from
A/California/7/2009,NYMCX-179Aastherepresen-
tative pandemic influenza A/H1N1 antigen and was
administered intramuscularly.
1 For this vaccine, adju-
vant and antigen were packaged separately and
required mixing before administration. The product
monographspecifieda0.25mLdoseoftheadjuvanted
vaccineforchildrenaged6monthsto9yearsanda0.5
mL dose for older children and adults.
1 National gui-
dance documents initially suggested a two dose sche-
dule spaced three weeks apart for children aged
6 months to 9 years,
13 but decisions about that were
subsequently adjusted at the provincial level owing to
the availability, sequencing, and roll-out of vaccine in
relation to the evolving epidemic curve. All
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monovalent and formalin inactivated, sodium deoxy-
cholate or sodium taurodeoxycholate (CSL Panvax)
split products,
14-16 containing 15 µg haemagglutinin of
the same antigen per 0.5 mL dose administered intra-
muscularly. Seasonal 2009-10 trivalent inactivated
influenza vaccine, supplied by two manufacturers
(domestically produced Fluviral, GlaxoSmithKline;
and imported Vaxigrip, Sanofi-Pasteur), was also avail-
able in Canada.
1718 As recommended by the World
HealthOrganization,the2009-10seasonalvaccinecon-
tained 15 µg haemagglutinin as split product derived
fromeachofA/Brisbane/59/2007(H1N1)-like,A/Bris-
bane/10/2007(H3N2)-like, and B/Brisbane/60/2008
(Victorialineage)-likeantigens.
19Administrationofsea-
sonal influenza vaccine was delayed in most provinces
of Canada pending the availability of pandemic vac-
cine, but it could be administered concomitantly in the
opposite limb.
12
Laboratory identification
The provincial laboratory of each participating pro-
vince tested for influenza viruses by real time reverse
transcription polymerase chain reaction according to
established protocols (web appendix B).
Vaccine effectiveness analysis
We estimated the effectiveness of vaccine by the test
negative incident case-control design as previously
described.
1011 Cases were participants in whom pan-
demicinfluenzaA/H1N1wasdetected;controlstested
negative for influenza A and B. Because influenza vac-
cine is recommended only for people aged at least
6 months, younger participants and those with
information on age missing were excluded. A consen-
sus view is that a period of at least 14 days is needed to
achieve a protective concentration of antibody after
influenza vaccination, but this timeline may vary.
20
Because the question related to the interval between
onset of influenza-like illness and immunisation was
dichotomised at two weeks, we could not further
explore the timeline to protection. We thus excluded
patients immunised less than two weeks before the
onset of illness. However, we also explored vaccine
effectiveness by including these patients in the vacci-
nated and unvaccinated categories.
Vaccinebecameavailableduringweek43,andinflu-
enzaactivitypeakedinweek44withlittleactivityafter
week 48 (figure). We thus selected weeks 45-48 as the
primary analysis period. Because uptake of pandemic
vaccine was evolving over the analysis period (figure),
estimates of coverage cannot be derived from this
study. For this reason also, we explored an element of
time in models of estimates of vaccine effectiveness.
We used logistic regression to estimate odds ratios
for the effect of pandemic H1N1 vaccine on medically
attended, laboratory confirmed pandemic influenza
A/H1N1 infection overall and among participants
under 50 years of age through sequential models with
adjustment for age (6 months to 9 years, 10-19 years,
20-49 years, and ≥50 years), chronic conditions (yes/
no), province (British Columbia, Alberta, Ontario, or
Quebec), timeliness of medical visit (≤4 days or
>4 days from the onset of influenza-like illness), and
week of onset of illness. We chose age categories on
the basis of recommendations on paediatric vaccine
dose/schedule that differed above and below 9 years
of age, as well as considerations related to pandemic
H1N1 risk differential, recognising that fewer cases
were reported among older adults. Sex was not
influential and was not included in any of the models.
We calculated vaccine effectiveness as (1−odds
ratio)×100.
21 In sensitivity analyses, we explored the
effect of varying analysis periods between weeks 44
and 52, varying definitions of vaccine status based on
interval in relation to illness onset, adjustment for day
(rather than week) of illness onset, receipt of seasonal
influenza vaccine, and restriction to participants with-
out comorbidity.
RESULTS
Influenza profile
The figure shows the epidemic curve of influenza test
result by onset of illness. During the primary analysis
periodbetweenweek45(8November)andweek48(5
December),867specimensweresubmitted.Becauseof
a delay in submission for ethics board approval in
Ontario, sentinel physicians in that province did not
have access to the revised 2009-10 questionnaire until
after 20 November (week 47). For this reason, a sub-
stantial proportion of specimens from Ontario were
submitted without pandemic H1N1 vaccine status
recorded and were thus excluded from the analysis.
Overall characteristics of patients excluded owing to
missing pandemic H1N1 vaccination status were
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Cases vaccinated ≥2 weeks before illness (%)
Controls vaccinated ≥2 weeks before illness (%)
Cases vaccinated (%)
Controls vaccinated (%)
Negative
Pandemic H1N1 positive
32 33 34 35 36 37 38 39 40 41 42 43
Pandemic H1N1 vaccine available to first group
44 45 46 47 48 49
Primary analysis period
50 51 52 1 2 3
Pandemic H1N1 vaccine
available to all
Pandemic H1N1 detections, and cumulative proportion vaccinated against pandemic H1N1
among cases and controls, by week (n=3898). Excludes specimens from patients who failed to
meet the influenza-like illness case definition or had unknown status; specimens collected >
7 days after influenza-like illness onset or with unknown interval; and patients with chronic
conditions unknown, age unknown, or influenza test results unavailable or inconclusive on
typing. One specimen positive for seasonal A/H1N1 (week 46) and four positive for seasonal
A/H3N2 (weeks 33, 41, 44, and 50) are not represented on graph. Primary analysis period
captures week 45 (8 November) to week 48 (5 December). Secondary analysis period captures
week 44 (1 November) to week 52 (31 December). Cumulative percentages for patients
vaccinated ≥2 weeks before illness onset exclude from numerator and denominator those
vaccinated <2 weeks before illness onset. Figure shows cumulative percentages vaccinated from
week 43 that are not directly comparable to proportions shown in table 3 for weeks 45-48
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(datanotshown).Afterweappliedinclusionandexclu-
sion criteria, 552 participants were available for the
primary analysis period (table 1).
Overall during the primary analysis period, 209
(38%) specimens were positive for pandemic H1N1
and no seasonal strains were detected (table 2). Influ-
enzapositivity variedby provinceandby weekofana-
lysis; 145/263 (55%), 57/144 (40%), 20/92 (22%), and
14/67(21%)sentinelspecimenswerepositiveoversuc-
cessive weeks 45-48. During the extended secondary
analysis period spanning weeks 44-52, 993 specimens
met the inclusion criteria, pandemic H1N1 was diag-
nosed in 411 (41%), and A/H3N2 was detected in 2
(0.2%) specimens, both from Quebec. No other seaso-
nal influenza viruses were detected.
Participant profile
Table 3 shows the distribution of detection of pan-
demic A/H1N1 by sex, age, province, chronic condi-
tions, and vaccine status. The distribution of
characteristics was similar between the primary and
secondary analysis periods (not shown). Young adults
aged 20-49 years made up the greatest proportion of
participants (44%), followed by children aged
6 months to 19 years (39%); fewer older adults aged
50-64 (12%) or 65 and over (4%) were included. The
proportion of patients who tested positive for pan-
demicH1N1variedbyage;itwashighestinthoseaged
10-19 years (42%), 6 months to 9 years (41%), and
20-49 years (40%); lower in adults aged 50-64 years
(30%); and lowest in people aged 65 years or over
(9%) (P=0.02). Overall, cases were slightly younger
than controls. The proportion with chronic conditions
was slightly higher among controls than among cases
(23% v 17%; P=0.06) and increased with age but was
generally comparable to the proportion observed for
controls during previous seasons (14-23%) and to esti-
mates from the Canadian Community Health Survey
(15-20%).
9-1122Theproportionimmunisedwith2008-9
seasonal vaccine among controls (28%) was slightly
lower than but comparable to that reported in a pre-
viouspublication(33%)andbytheCanadianCommu-
nity Health Survey (32%).
1123 A detailed comparison
ofcharacteristicsbetweencontrolswhodidanddidnot
receive the pandemic H1N1 vaccine is also shown in
web appendix C.
Pandemic H1N1 was detected in a greater propor-
tionofspecimenscollectedwithinfourdaysofonsetof
illness (190/487; 39%) compared with specimens col-
lected at 5-7 days (19/65; 29%) (P=0.13). The propor-
tion of cases (190/209; 91%) and controls (297/343;
87%) whose specimens were collected at or before
four days was comparable (P=0.13) and did not vary
among those with (99/115; 86%) or without (388/
437; 89%) chronic conditions (P=0.42); it did vary
slightly among vaccinated (48/60; 80%) compared
with unvaccinated participants (439/492; 89%)
(P=0.036) (table 3).
Immunisation profile
During the primary analysis period, 11% (60/552) of
participants reported receipt of pandemic H1N1 vac-
cineat leasttwoweeksbefore onsetofillness.Thepro-
portion who reported receipt of pandemic H1N1
vaccine varied with age and comorbidity (table 3).
Information on the type of vaccine received was
recorded by only 21/60 (35%) vaccine recipients, but
all reported receiving the adjuvanted formulation.
During the secondary analysis period, 52/108 (48%)
vaccinated participants reported the type of vaccine
they had received, and of these 96% (50/52) reported
receiving the adjuvanted formulation. During the pri-
mary analysis period, all vaccinated participants
reportedhavingreceivedasingledose.Duringthesec-
ondary analysis period, two children (4 and 8 years of
age) reported two dose immunisation.
During the primary analysis period, just two vacci-
nated cases were identified (table 3). One of the two
vaccine failures was a healthy 9 year old child from
Quebec with onset of influenza-like illness in mid-
November. The other was a young adult with under-
lyingcomorbidityfromBritishColumbiawithonsetof
illness in the second half of November. Only 29/517
(6%) participants reported receipt of the 2009-10 sea-
sonal vaccine, and of these 13 (45%) had also received
the pandemic H1N1 vaccine.
Vaccine effectiveness estimates
Table 4 provides estimates of vaccine effectiveness
overall and among participants under 50 years of age
for the primary analysis period with and without
adjustment, followed by sensitivity analyses and
restrictions applied to that period. It also gives esti-
mates for varying intervals within the secondary ana-
lysis period. The crude estimate of vaccine
effectiveness during the primary analysis period was
95% (95% confidence interval 80% to 99%), and this
changed only slightly with full adjustment to 93%
(69% to 98%).
Table 1|Inclusion and exclusion of participants for specimens submitted during primary
analysis period spanning onset of illness from week 45 (8 November 2009) to week 48 (5
December 2009)
Exclusion criteria No excluded No included
Specimen submitted from consenting patients 0 866
Influenza-like illness presentation not met or unknown 31 835
Specimen collected >7 days after onset of influenza-like illness*
or interval unknown
22 813
Chronic conditions unknown 63 750
Age unknown or <6 months 7 743
Influenza RT-PCR results unavailable or inconclusive 6 737
Pandemic H1N1 vaccine status missing or unknown 136† 601
Pandemic H1N1 vaccine received <2 weeks before onset
of influenza-like illness*
49 552
Contributed to analysis 0 552
RT-PCR=reverse transcription polymerase chain reaction.
*Defined as acute onset of fever and cough and one or more of sore throat, arthralgia, myalgia, and prostration.
†Because of delay in submission for annual ethics approval in Ontario, sentinel physicians in that province did
not have access to revised 2009-10 questionnaire until after 20 November (week 47); 75/122 of specimens
from Ontario had unknown pandemic H1N1 vaccine status and were excluded from analysis.
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least90%,wererobustandmaintainedacrossmostsen-
sitivity analyses. Altering the paediatric age categories
selected for adjustment to include preschool children
and younger and older school age children did not
meaningfully alter estimates of vaccine effectiveness
(available on request). The week (or date) of onset of
illness was the only covariate that influenced estimates
of vaccine effectiveness. As anticipated, an interval
afterimmunisationwasneededforoptimalprotection.
If participants who had received vaccine within two
weeks of onset of illness were returned to the analysis
as vaccinated, estimates dropped considerably to 55%
(20% to 75%). If those vaccinated within two weeks
were instead considered to be unvaccinated, fully
adjusted vaccine effectiveness was the same as in the
primary analysis. Receipt of 2008-9 or 2009-10 seaso-
nalvaccinehad minimalinfluenceontheeffectiveness
of pandemic H1N1 vaccine in multivariable analysis.
Fully adjusted estimates of vaccine effectiveness
were lower (78%, 53% to 90%) during the secondary
analysis period spanning weeks 44-52. We had anti-
cipated this, given that roll-out of vaccine had begun
only one week earlier and a larger number of controls
without opportunity to receive vaccine were included
in week 44 (figure). Estimates of vaccine effectiveness
increased during the secondary analysis period when
restriction started instead at week 45 (87%, 62% to
95%) and were again comparable to the primary ana-
lysis period with later restriction or for weeks 46-47.
DISCUSSION
Using the sentinel physician surveillance system in
Canada, we measured excellent protection conferred
by a single dose of the monovalent AS03 adjuvanted
pandemic vaccine during the autumn 2009 epidemic
in Canada. Specifically, 14 days or more after vaccina-
tion, we estimated vaccine effectiveness of 93% (95%
confidence interval 69% to 98%) against medically
attended, laboratory confirmed pandemic influenza
A/H1N1 illness. This estimate was robust and main-
tained (≥90%) across most sensitivity analyses and pri-
marily reflects protection conferred to children and
young adults.
Comparison with other studies
Our estimates of protection by vaccine are consistent
withimmunogenicitystudiesindicatingveryhighanti-
body response to AS03 adjuvanted pandemic H1N1
vaccine across age groups,
13-5 as well as with the pro-
tection that would be expected given excellent match
of vaccine to circulating virus. The findings are also
consistent with recent estimates of vaccine effective-
ness derived in a smaller test negative case-control
study among children under 10 years of age in New
Brunswick, Canada (28 cases (none vaccinated); 63
controls (24 vaccinated)) given a single dose of the
same product (100%, 79.5% to 100%).
24 Our results
are also consistent with study findings based on the
screening method in Germany among patients aged
14 years and over given the AS03 adjuvanted pan-
demic H1N1 vaccinemanufactured by GlaxoSmithK-
line in Dresden.
25 In that study, vaccine effectiveness
among participants aged 14-59 years was 96.8%
(95.2% to 97.9%) and slightly lower in those aged
60 years or over (83.3%, 71.0% to 90.5%).
25 A retro-
spective cohort study from Scotland across all age
groups similarly reported protection by vaccine of
95% (76% to 100%), but the proportionate mix and
type(s) of vaccine used were not specified.
26 Our esti-
mates are higher than those based on the test negative
case-control design applied to a linked monitoring
network across seven countries of Europe, in which
participants received a mix of adjuvanted and non-
adjuvanted formulations; additional methodological
differences may also explain their lower estimate of
vaccine effectiveness of 71.9% (45.6% to 85.5%).
27 As
with all observational designs, the relative strengths
and weaknesses, and potential for bias and confound-
ing, have to be taken into account in interpreting each
of these datasets. In particular, distribution of pan-
demic vaccine was progressing as the autumn H1N1
epidemic was evolving in many countries. Considera-
tion of detail related to the change in immunisation
coverage among controls over the course of the analy-
sis period is essential for each of these studies.
Strengths and limitations of study
Strengths of our study include the almost sole use
of a single vaccine formulation—thus simplifying
Table 2|Laboratory profile of specimens included during primary analysis period spanning onset of illness from week 45 (8
November 2009) to week 48 (5 December 2009). Values are numbers (percentages)
Specimen included Alberta (n=96) British Columbia (n=209) Ontario (n=33) Quebec (n=217) Total (n=555)
Influenza negative 66 (69) 133 (64) 31 (94) 113 (52) 343 (62)
Influenza positive: 30 (31) 76 (36) 2 (6) 104 (48) 212 (38)
A positive 30 (100) 76 (100) 2 (100) 104 (100) 212 (100)
B positive 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Influenza A positive:
A/H1N1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
A/3N2 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Pandemic A/H1N1 30 (100) 76 (100) 2 (100) 101 (97) 209 (99)
Subtype unknown 0 (0) 0 (0) 0 (0) 3 (3) 3 (1)
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itoringofvaccineeffectivenessthathasbeenrehearsed
across several seasons in Canada (since 2004).
8-11 In
general, adjusted point estimates of the effectiveness
of (non-adjuvanted) influenza vaccine against seasonal
strains based on this sentinel surveillance system in
Canada have ranged between 50% and 60%
overall.
8-11 Estimates from the sentinel system have
beencomparabletoavailableresultsfromrandomised
controlled trials in the United States using the Cana-
dianGlaxoSmithKlinevaccineduringthecorrespond-
ing season (2005-6 and 2006-7).
28 Estimates of vaccine
effectiveness have also been well correlated in compo-
nent specific analyses with the relative match/mis-
match of vaccine antigens to circulating strains. With
a good match, such as between the A/H1N1 compo-
nent of the 2006-7 (non-adjuvanted) vaccine and the
then circulating virus (A/NewCaledonia/20/99
(H1N1)-like), vaccine effectiveness was also found to
exceed90%whenmeasuredbythissystem.
10Afurther
advantage of the sentinel system is its breadth of
representation, including more than 500 sentinel sites
spanning four provinces. Such geographical breadth
becomes a particular strength in capturing variation in
circulating viruses and when pursuing the rare event of
vaccine failure in the context of highly immunogenic
vaccine. In our analysis, adjustment by week of onset
of illness and exploration over varying time periods in
sensitivity analyses made the effect of co-evolving epi-
demic activity and vaccine roll-out explicit.
Limitationsofthesentinelsystemformonitoringvac-
cineeffectivenesshavebeendescribedpreviously.
8-11In
particular, despite study protocols, standardised ques-
tionnaires, instruction kits, and ethics review, the senti-
nel system remains a public health surveillance
approach so that monitoring of vaccine effectiveness is
not as rigorous as in controlled clinical trials. The test
negative design superimposed on this system is an
observationalcase-controlmethod,andthesameepide-
miological considerations as with any case-control
study still apply. This approach cannot guard against
thesystematicinfluencesofbias(selection,information)
orunmeasuredconfounders.Wecarefullyassessedpar-
ticipants’profilesagainsthistoricalandexpecteddemo-
graphic information as a flag for possible evidence of
selection bias. Despite reassuring profiles, however,
this still cannot be fully ruled out. We required partici-
pants to have presented to a physician with influenza-
like illness, thus standardising in part, but not fully, for
healthcareseekingbehaviour, accesstohealthcare, and
severityofillness.However,clinicians’discretioninthe
decision to test is recognised.
Althoughthiswasnot a blindedclinicaltrial,we col-
lected information on vaccine before the physician or
patient knew the influenza test result, thus helping to
reduce recall bias. We have interpreted results as
reflecting the AS03 adjuvanted vaccine most used in
Canadaonthebasisofrelativedistributionandlimited
access to the unadjuvanted formulation, but most vac-
cinated participants did not know or report the type of
vaccine they received. We collected information on
Table 3|Pa rt ic ip an ts ’ profile for primary analysis period spanning onset of illness from week
45 (8 November 2009) to week 48 (5 December 2009). Values are numbers (column
percentages)
Covariates
Pandemic H1N1 test
negative control
(n=343)
Pandemic H1N1 test
positive case
(n=209)
Overall
(n=552)
Age category:
6 months to 9 years 71 (21) 50 (24) 121 (22)
10-19 years 56 (16) 40 (19) 96 (17)
20-49 years 148 (43) 97 (46) 245 (44)
50-64 years 47 (14) 20 (10) 67 (12)
≥65 years 21 (6) 2 (1) 23 (4)
Median (range) age (years) 27 (<1-88) 22 (<1-68) 24 (<1-88)
Female sex 200 (58) 93 (45) 293 (53)
Chronic conditions 80 (23) 35 (17) 115 (21)
Province:
A l b e r t a 6 6( 1 9 ) 3 0( 1 4 ) 9 6( 1 7 )
British Columbia 133 (39) 76 (36) 209 (38)
Ontario 31 (9) 2 (1) 33 (6)
Quebec 113 (33) 101 (48) 214 (39)
Pandemic H1N1 vaccinated* 58 (17) 2 (1) 60 (11)
2009-10 seasonal vaccine:
Not vaccinated 297 (93) 191 (97) 488 (94)
Vaccinated 24 (7) 5 (3) 29 (6)
2008-9 seasonal vaccine:
Not vaccinated 213 (72) 158 (84) 371 (77)
Vaccinated† 83 (28) 29 (16) 112 (23)
Specimen collection interval:
≤4 days after illness onset 297 (87) 190 (91) 487 (88)
5-7 days after illness onset 46 (13) 19 (9) 65 (12)
Median (range) days 2 (0-7) 2 (0-7) 2 (0-7)
Pandemic H1N1 vaccination by age:
6 months to 9 years 22/71 (31) 1/50 (2) 23/121 (19)
10-19 years 3/56 (5) 0/40 (0) 3/96 (3)
20-49 years 21/148 (14) 1/97 (1) 22/245 (9)
50-64 years 11/47 (23) 0/20 (0) 11/67 (16)
≥65 years 1/21 (5) 0/2 (0) 1/23 (4)
Chronic conditions by age:
6 months to 9 years 11/71 (15) 6/50 (12) 17/121 (14)
10-19 years 8/56 (14) 9/40 (23) 17/96 (18)
20-49 years 29/148 (20) 12/97 (12) 41/245 (17)
50-64 years 18/47 (38) 7/20 (35) 25/67 (37)
≥65 years 14/21 (67) 1/2 (50) 15/23 (65)
With chronic conditions:
N o tp a n d e m i cH 1 N 1v a c c i n a t e d 5 9( 7 4 ) 3 4( 9 7 ) 9 3( 8 1 )
Pandemic H1N1 vaccinated 21 (26) 1 (3) 22 (19)
Without chronic conditions:
Not pandemic H1N1 vaccinated 226 (86) 173 (99) 399 (91)
Pandemic H1N1 vaccinated 37 (14) 1 (1) 38 (9)
Interval to specimen collection ≤4 days:
Not pandemic H1N1 vaccinated 251 (85) 188 (99) 439 (90)
Pandemic H1N1 vaccinated 46 (15) 2 (1) 48 (10)
Interval to specimen collection 5-7 days:
Not pandemic H1N1 vaccinated 34 (74) 19 (100) 53 (82)
Pandemic H1N1 vaccinated 12 (26) 0 (0) 12 (18)
*Received vaccine ≥2 weeks before onset of illness; excludes from numerator and denominator those
immunised <2 weeks before onset.
†Excludes children too young to have received 2008-9 seasonal vaccine.
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effectiveness (age, chronic conditions, timeliness of
specimen collection) and adjusted for recognised con-
founderstestedoverseveralyearsofapplicationofthis
system in Canada. Some information, such as on
chronicconditions,isdichotomisedinayes/noformat
withoutfurtherdetailprovided.Althoughthismaynot
represent finer differential across specific conditions,
littleeffectofresidualconfoundinghasbeenattributed
to aggregation of comorbidity in studies of influenza
vaccination.
29 Ultimately, however, residual con-
founding cannot be ruled out.
Canada delayed the administration of the 2009-10
seasonal influenza vaccine until pandemic vaccine
became available. This prevented us from assessing
the effect of its previous administration on response
Table 4|Effectiveness of vaccine against medically attended, laboratory confirmed pandemic H1N1, including additional
sensitivity analyses
Vaccine effectiveness* (95% CI) (No of cases; No of controls)
Overall Aged <50 years
Covariates in primary analysis— —weeks 45-48 (8 November to 5 December 2009)
Unadjusted 95.3 (80.3 to 98.9) (209; 343) 94.6 (77.5 to 98.7) (187; 275)
Chronic conditions (yes/no) 95.1 (79.5 to 98.8) (209; 343) 94.6 (77.3 to 98.7) (187; 275)
Age† 95.6 (81.4 to 98.9) (209; 343) 95.0 (79.0 to 98.8) (187; 275)
Province (BC, AB, ON, QC) 95.2 (80.1 to 98.9) (209; 343) 94.5 (76.9 to 98.7) (187; 275)
Specimen collection interval (≤4/>4 days) 95.1 (79.9 to 98.8) (209; 343) 94.6 (77.2 to 98.7) (187; 275)
Week of illness onset 93.2 (71.5 to 98.4) (209; 343) 91.5 (63.9 to 98.0) (187; 275)
Age and chronic conditions† 95.5 (81.1 to 98.9) (209; 343) 95.0 (78.8 to 98.8) (187; 275)
Age, chronic conditions, province† 95.5 (81.0 to 98.9) (209; 343) 94.9 (78.3 to 98.8) (187; 275)
Age, chronic conditions, province, specimen collection interval† 95.5 (80.8 to 98.9) (209; 343) 94.9 (78.2 to 98.8) (187; 275)
Age, chronic conditions, province, specimen collection interval,
week of illness onset†
92.7 (68.6 to 98.3) (209; 343) 91.1 (61.5 to 98.0) (187; 275)
Variations applied to primary analysis period (weeks 45-48)
Excluding Ontario†‡ 92.2 (66.5 to 98.2) (207; 312) 90.4 (57.9 to 97.8) (185; 253)
Restricted to only those with no chronic conditions†§ 95.6 (66.8 to 99.4) (174; 263) 95.3 (63.7 to 99.4) (160; 227)
Including those with unknown chronic conditions as “no chronic condition”†‡ 92.8 (69.4 to 98.3) (216; 370) 91.1 (61.5 to 97.9) (192; 297)
Including those with unknown chronic conditions as “with chronic condition”†‡ 92.5 (67.9 to 98.2) (370; 216) 91 (61 to 97.9) (297; 192)
Age, chronic conditions, province, specimen collection interval,
day of illness onset†
92.3 (67.3 to 98.2) 90.5 (58.8 to 97.8)
As above, restricted to only those with no chronic conditions†§ 95.3 (64.3 to 99.4) (174; 263) 94.8 (60.2 to 99.3) (160; 227)
Pandemic H1N1 vaccine status unknown considered as “unvaccinated”†‡ 93.1 (70.6 to 98.4) (214; 350) 91.6 (63.6 to 98.0) (191; 281)
As above, restricted to only those with no chronic conditions†§ 95.6 (66.5 to 99.4) (175; 270) 95.2 (63.4 to 99.4) (161; 233)
Pandemic H1N1 vaccine status unknown considered as “vaccinated”†‡ 75.9 (43.9 to 89.7) (350; 214) 75.6 (38.9 to 90.3) (281; 191)
As above, restricted to only those with no chronic conditions†§ 92.0 (65.2 to 98.2) (270; 175) 91.4 (62.3 to 98.0) (233; 161)
Pandemic H1N1 vaccine interval <2 weeks considered vaccinated†‡ 55.2 (19.8 to 75.0) (225; 376) 54.6 (14.8 to 75.9) (201; 300)
As above, restricted to only those with no chronic conditions†§ 64.0 (26.0 to 82.5) (184; 285) 70.2 (34.4 to 86.4) (168; 246)
Pandemic H1N1 vaccine interval <2 weeks considered unvaccinated†‡ 92.6 (68.5 to 98.3) (225; 376) 91.1 (61.3 to 97.9) (201; 300)
As above, restricted to only those with no chronic conditions†§ 95.4 (64.7 to 99.4) (184; 285) 94.9 (60.9 to 99.3) (168; 246)
Age, chronic conditions, province, specimen collection interval, week of illness
onset, receipt of 2008-9 seasonal vaccine†
88.0 (46.9 to 97.3) (187; 296) 85.2 (32.9 to 96.7) (167; 235)
As above, restricted to only those with no chronic conditions†§ 92.3 (38.4 to 99.0) (158; 225) 91.8 (33.9 to 99.0) (144; 192)
Age, chronic conditions, province, specimen collection interval, week of illness
onset, receipt of 2009-10 seasonal vaccine†
94.8 (60.5 to 99.3) (196; 321) 93.4 (48.2 to 99.2) (176; 256)
As above, restricted to only those with no chronic conditions†§ 92.3 (39.1 to 99.0) (165; 246) 91.3 (30.4 to 98.9) (152; 210)
Restricted to only those with specimen collection interval ≤4d a y s †¶ 90.9 (60.5 to 97.9) (190; 297) 88.8 (50.6 to 97.4) (171; 244)
Variations in analysis period (illness onset)**
Weeks 44-52 (1 November to 31 December 2009)†‡ 78.4 (52.6 to 90.2) (411; 577) 75.1 (44.5 to 88.8) (372; 470)
Weeks 45-52 (8 November to 31 December 2009)†‡ 86.7 (61.8 to 95.4) (217; 457) 84.1 (53.5 to 94.6) (194; 361)
Weeks 47-52 (22 November to 31 December 2009)†‡ 92.5 (41.0 to 99.0) (36; 268) 91.7 (33.8 to 99.0) (29; 211)
Weeks 46-47 (15 November to 28 November 2009)†‡ 92.6 (41.8 to 99.1) (65; 165) 92.4 (39.3 to 99.0) (58; 138)
*Vaccine effectiveness=(1−odds ratio)×100.
†Adjusted for age as 6 months to 9 years, 10-19 years, 20-49 years, and ≥50 years for overall and as 6 months to 9 years, 10-19 years, and
20-49 years for <50 years.
‡Adjusted for age, province, chronic conditions (yes/no), interval since influenza-like illness onset (≤4/>4 days), and week of illness onset.
§Adjusted for age, province, interval since influenza-like illness onset, and week of illness onset.
¶Adjusted for age, province, chronic conditions, and week of illness onset.
**During secondary analysis period (weeks 44-52), eight cases had received pandemic H1N1 vaccine >2 weeks before illness onset, including five
children aged 1-9 years and three young adults aged 20-49 years; of these eight pandemic H1N1 vaccine failures, six cases reported no underlying
conditions.
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surveillance network, the number of vaccine failures
identified in this study was small, a limitation difficult
to overcome in the context of highly immunogenic
vaccine. This precluded stratified analysis (such as
age specific estimates of vaccine effectiveness) and
may potentially limit the meaningfulness of extensive
multivariable adjustmentorsensitivityanalysis.Given
that more than 80% of our participants were under
50 years of age, our estimates of protection by vaccine
cannot be reliably interpreted for older adults. Further
evidence for effectiveness in older people is needed.
Conclusions
Wereportestimatesofvaccineeffectivenesssuggesting
very high protection conferred by a single dose of the
monovalent AS03 adjuvanted pandemic vaccine most
used in Canada during autumn 2009, with reference in
particular to children and young adults. Although lim-
ited bya small number ofvaccinefailures, weinterpret
thesefindingstobeconsistentwithindicatorsofimmu-
nogenicity showing very high vaccine induced anti-
body response and with virological characterisation
suggesting an excellent match of vaccine to circulating
virus. Our findings are relevant to the evaluation of
pandemic vaccination efforts not only in Canada but
also in other countries where adjuvanted vaccines
were used. Our results may help to inform the further
development of influenza vaccine options.
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